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A 37-year-old caucasian female patientwas referred to the dermatology unit of the Hosp- ital de Poniente, El Ejido, Spain, in 2017 with 
alopecia totalis (AT). The AT had occurred over the past 
five months and was classified as grade IV (75–100% 
hair loss) severity alopecia tool index (SALT) [Figure 1]. 
No nail changes were found prior to treatment.
Previous failure of topical treatments (high potency 
corticosteroids, diphenylcyclopropenone and minoxidil 
5%), infiltration of intralesional corticosteroids (triamci- 
nolone acetonide/mepivacaine 2% at 2 mL/month for 
six months) and dexamethasone minipulses (0.1 mg/kg 
twice a week for six months) was reported. There was 
no personal or family history of alopecia areata. Following 
approval of the hospital’s pharmaceutical committee, 
treatment with tofacitinib 5 mg/12 hours was prescribed 
five months after the last unsuccessful treatment (dexa- 
methasone minipulses). Complete blood count, liver and 
kidney function tests, electrolytes, thyroid function, sero- 
logy tests for hepatitis B and C, HIV and tuberculin 
skin test were within normal ranges.
A 40% regrowth of the hair of the scalp was 
observed at three months [Figure 2]. At six months, 
the patient’s remaining hair loss was equivalent to 
SALT I (less than 25% total hair loss) with a substantial 
improvement of her quality of life as recored on the 
dermatology quality of life index from 25 to 3 [Figure 
3]. Routine biochemical tests, such as hepatic and 
kidney function tests and lipid profile showed no 
anomalies during the course of the treatment. The 
patient is currently continuing treatment with no side 
effects reported for the previous 10 months.
Comment
Tofacitinib is an inhibitor of Janus kinase-3 and is 
approved by the Food and Drug Administration for the 
treatment of rheumatoid arthritis (RA). Craiglow and 
King first observed the effectiveness of tofacitinib in 
the treatment of alopecia areata.1 Subsequently, retros- 
pective studies with more than 90 patients and clinical 
trials using the dosage approved for RA evaluated its 
short- and medium-term effectiveness.2 Alopecia areata 
is considered an autoimmune disease with a 1.7% incid- 
ence rate. Scalp biopsy will not help in determining the 
cause of alopecia in such patients.
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Figure 1: Photographs of the scalp of a 37-year-old female patient showing alopecia totalis, which is an advanced form 
of alopecia areata.
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Treatment with tofacitinib may be adapted according 
to previously reported cases.3 Frequent side effects 
include grade I and II infections, transaminitis and temp- 
orary cholesterol elevations. Nevertheless, doses greater 
than 10 mg twice a day may be associated with an 
increased risk of serious infections and malignancies.2 
The SALT score will be imperative to determine the 
severity and monitor the response to treatments, using 
either the original SALT I or SALT II (determined by 
adding the percentage of hair loss in various areas of 
the scalp).
Analysis of gene expression can be crucial to 
identify non-responders and slow responders and adjust 
the treatment in a timely manner. Further research to 
determine protocols of use, monotherapy and combined 
therapy and monitoring the side effects of alopecia 
areata are required. Unfortunately, the discontinuation 
of tofacitinib can cause relapse of the alopecia.3
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Figure 2: Photographs of the scalp of a 37-year-old female 
patient after three months of treatment with tofacitinib.
 
Figure 3: Photographs of the scalp of a 37-year-old female 
patient after six months of treatment with tofacitinib.
